Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma (SYSTHER)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01021800
Verified November 2009 by Blood Transfusion Centre of Slovenia. Recruitment status was: Recruiting
Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
ECOG performance status 0-2 at the time of inclusion
Following R0 or R1 pancreatic tubular adenocarcinoma resection and adjuvant gemcitabine treatment